Drug resistance

Two new webinars on global approaches to integrase inhibitor drug resistance

Drug resistance or side effects might limit ART in up to 1 in 10 people living with HIV

Five cases of viral failure on CAB-LA and RPV-LA injections

IAS 2023: High rates of re-suppression with dolutegravir in the ADVANCE study

Tracking HIV A6 strain in Europe: implications for injectable CAB-LA for treatment or PrEP

IAS-USA update HIV drug resistance tables

CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study

Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART

Superinfection detected in up to 7% of people in Swiss HIV Cohort Study

Low levels of RPV-LA might explain failure with injectable ART despite perfect adherence

Update to IAS-USA drug resistance tables

Drug resistance profile of integrase inhibitors when treating HIV-2

Lenacapavir: drug resistance after viral rebound in treatment experienced participants

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

UK study for people with triple-class drug resistance

Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study      

High rates of drug resistance and virological failure among adults with HIV admitted to hospital in Malawi

IAS–USA update of drug resistance mutations (2019)

27th International Workshop on HIV Drug Resistance and Treatment Strategies

Drug resistance in low- and middle-income countries

M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy

Bictegravir at CROI 2018: switching studies and drug resistance analyses

Early ART is not associated with a higher risk of HIV drug resistance

Publications launched at IAS 2017

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

Achieving viral suppression with HIV multi-drug resistance: peg-interferon and valaciclovir as part of rescue therapy

No transmission of integrase-resistant HIV seen in California cohort

Transmitted drug resistance in HIV positive pregnant women

XXIV International HIV Drug Resistance Workshop
, 21-22 February 2015, Seattle, Washington

Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

Drug resistance and integrase inhibitors: potential impact of HIV subtype

Drug resistance in children after PMTCT and early treatment

Genotyping using dried blood spots in rural South African setting

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

Dolutegravir update: drug resistance in people who are treatment-naive and -experienced

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance

In vitro resistance profile for BMS 986001

Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B

Defective viral reservoir populations is common in patients on long-term suppressed ART

First case report of transmission with five-class resistance

New data on the Berlin patient: interpret with caution

Free online resource for treatment decisions without access to genotype resistance tests

Minority M184V variants detected in women after receiving 3TC/FTC and LPV/r-containing regimens in pregnancy

Novel mutations and shifting susceptibility to darunavir and tipranavir

Darunavir-associated mutations in PI-naive and PI-experienced children in the UK

Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens

Transmitted multidrug-resistant HIV persists in PBMC DNA for years

Low-level Q148R in people without integrase inhibitor experience

Cut-offs suggested for predicting efavirenz failure with low-level K103N

Lower M184V rates with FTC/TDF than with 3TC/TDF

HBV resistance to lamivudine at undetectable and low levels of viremia

Integrase inhibitor resistance and cross-resistance: weighing viral fitness and the option to benefit from second-generation compounds

Understanding etravirine susceptibility: new weighted genotype score and phenotypic cut-offs

Lack of virological impact of treatment intensification in suppressed patients supports latent viral reservoir as source of residual viraemia

NNRTI resistance in infants prophylaxed with single-dose nevirapine varies by the timing of infection

Detecting viral tropism: impact of a more sensitive Trofile (ES) assay

Low frequency K103N mutations are associated with poor virological response to NNRTI based therapy

Background drugs and low maraviroc levels explain resistance in Motivate studies

Post navigation